Clinical Trials List
2022-02-01 - 2026-12-31
Phase II/III
Recruiting4
ICD-10D47.4
Osteomyelofibrosis
ICD-10D68.51
Activated protein C resistance
ICD-10D68.52
Prothrombin gene mutation
ICD-10D68.59
Other primary thrombophilia
ICD-10D68.61
Antiphospholipid syndrome
ICD-10D68.62
Lupus anticoagulant syndrome
ICD-10D68.69
Other thrombophilia
ICD-10D75.81
Myelofibrosis
ICD-10D75.89
Other specified diseases of blood and blood-forming organs
ICD-10D77
Other disorders of blood and blood-forming organs in diseases classified elsewhere
ICD-10D89.2
Hypergammaglobulinemia, unspecified
ICD-10E88.09
Other disorders of plasma-protein metabolism, not elsewhere classified
ICD-9289.8
Other specified diseases of blood and blood-forming organs
-
Trial Applicant
PAREXEL INTERNATIONAL CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- SHAN-CHI YU Division of Hematology & Oncology
- Wen-Chien Chou Division of Hematology & Oncology
- - - Division of Hematology & Oncology
- CHENG-HONG TSAI Division of Hematology & Oncology
- Shang-Ju Wu Division of Hematology & Oncology
- MING YAO Division of Hematology & Oncology
- 劉高郎 Division of Hematology & Oncology
- - - Division of Hematology & Oncology
- Chien-Chin Lin Division of Hematology & Oncology
- BANG-BIN CHEN Division of Hematology & Oncology
- 田豐銘 Division of Hematology & Oncology
- Huai-Hsuan Huang Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Ming-Yu Lien Division of Hematology & Oncology
- Ching-Chan Lin Division of Hematology & Oncology
- 陳珈妤 Division of Hematology & Oncology
- 王秀慈 Division of Hematology & Oncology
- Chi-Ching Chen Division of Hematology & Oncology
- Ming-Hung Tsai Division of Hematology & Oncology
- Che-Hung Lin Division of Hematology & Oncology
- Tzu-Ting Chen Division of Hematology & Oncology
- 鄭富銘 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Jeng-Shiun Du Division of Hematology & Oncology
- 莊哲明 Division of Hematology & Oncology
- Hui-Ching Wang Division of Hematology & Oncology
- 高育青 Division of Hematology & Oncology
- Shih-Feng Cho Division of Hematology & Oncology
- Tsung-Jang Yeh Division of Hematology & Oncology
- 柯亞倫 Division of Hematology & Oncology
- Yi-Chang Liu Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
10 participants
-
Global
385 participants
